For sales, marketing, medical affairs, pricing, and compliance staff. Off-label promotion, kickbacks, and pricing fraud that reach Medicare and Medicaid can violate the False Claims Act, and insiders with firsthand evidence may receive 15–30% of the government's recovery.
Submit Your InformationIt is a drug or device company causing false claims to Medicare, Medicaid or other federal programs, for example through kickbacks to prescribers, off-label promotion, or false price reporting that cuts Medicaid rebates. Claims resulting from an Anti-Kickback Statute violation are false claims by law (42 U.S.C. § 1320a-7b(g)). GlaxoSmithKline paid $3 billion in 2012 to resolve criminal and civil liability over such conduct (DOJ, 2012).
Your information should come from direct knowledge, such as call notes, sales targets, speaker program records, pricing and rebate calculations, or internal communications. Timing matters: a case generally must be filed within six years of the violation, and never more than ten. (31 U.S.C. § 3731(b))
False Claims Act qui tam cases are filed under seal for at least 60 days, meaning the complaint stays confidential while the government investigates and decides whether to intervene. (31 U.S.C. § 3730(b)(2))
If the government intervenes, the whistleblower (called a "relator") generally receives 15–25% of the recovery. If it declines and the relator pursues the case, the share is 25–30%. Courts can award less, for example when a case relies mainly on publicly disclosed information. (31 U.S.C. § 3730(d))
Promoting drugs for uses the FDA has not approved, causing claims to Medicare or Medicaid for uses those programs do not cover. Pfizer's 2009 resolution included $1 billion under the False Claims Act, and six whistleblowers received more than $102 million. (DOJ, 2009)
Sham speaker programs, honoraria, meals, or consulting fees paid to induce prescriptions. Claims resulting from an Anti-Kickback Statute violation are false claims under the False Claims Act. (42 U.S.C. § 1320a-7b(g))
Events with little or no educational content that reward high prescribers. Novartis paid $678 million in 2020 to resolve allegations of this kind first brought to the government by a whistleblower. (DOJ, 2020)
Misreporting prices or misclassifying products to underpay Medicaid drug rebates. Mallinckrodt agreed in 2022 to pay about $234.7 million on rebate allegations, and the whistleblower received about $24.7 million. (DOJ, 2022)
Using a charity or foundation as a conduit to cover patients' copays for a company's own drug. About $26.3 million of the same Mallinckrodt resolution concerned allegations of this kind. (DOJ, 2022)
Selling adulterated drugs made in violation of manufacturing standards to government programs. GSK's 2010 resolution included a $600 million civil settlement, and the whistleblower received about $96 million. (DOJ, 2010)
False Claims Act recoveries exceeded $6.8 billion in fiscal year 2025, the most in the law's history, and more than $5.7 billion involved the health care industry. Prescription drugs were one of three health care areas the Justice Department highlighted. A company found liable generally owes up to three times the government's damages, plus a penalty for each false claim.
Source: U.S. Department of Justice, January 16, 2026; 31 U.S.C. § 3729(a)(1)
For pharmaceutical and life sciences fraud claims with estimated damages exceeding $1M
This intake only handles reports from insiders about fraud by an organization, so we are not the right fit for this matter. The agencies below accept reports like yours directly.